Consistently, a case study has demonstrated a significant and durable response to pembrolizumab of a patient with relapsed stage IB LCNEC with PD-L1-negative tumor that was positive for PD-L1 amplification and high TMB [13]. This evidence concerns the gene CD274 and neoplasm.